DNAe Unveils Early Access Program for LiDia-SEQ™: Hospital Teams Invited to Trial DNAe’s Flagship Tests

New priority program opens up exclusive opportunities for collaborative research on transformative clinical potential of DNAe’s flagship tests and to gain preview of breakthrough LiDia-SEQ™ platform.

London, UK and Carlsbad, CA, USA – December 11 2025: DNAe, the Next-Generation Sequencing (NGS) company developing a transformative fully automated, sample-to-report diagnostics platform, today unveils a new Early Access Program, offering clinical partners an exclusive pre-launch preview of the results generated by the company’s world-first tests* – including the BSI/AMR Test targeting bloodstream infections and antimicrobial resistance – and the opportunity to later participate in pilot placements of DNAe’s breakthrough Next Generation Sequencing (NGS)-based diagnostic system – LiDia-SEQ™.